The performer teams are led by:

- **Alden Scientific**, in Cambridge, MA, which will provide multi-omics analysis (e.g., proteomics, genomics) to assess physiological changes that may also indicate mental health state and change.
- **Attune Neurosciences**, in San Francisco, which will provide data and insights from the use of its low-intensity-focused-ultrasound to deliver neuromodulation therapy for chronic pain and depression.
- **Motif Neurotech**, in Houston, which seeks to accelerate measures of neuromodulation by leading adjunctive data collection.
- **NeuroFlow, Inc.**, Philadelphia, which is developing a population-scale framework for evaluating rapid-acting behavioral health interventions against real-world standard care baselines.
- **INVI MindHealth,** in Denver, which is augmenting behavioral health research in neuromodulation and psychedelic therapies with a platform for real-time objective biomarkers as new endpoints for rapidly determining treatment efficacy.
- **Diamond Therapeutics**, in Toronto, which, in partnership with **Tactical Mind Research Coalition**, in St. Petersburg, FL, will contribute data from a phase 2a clinical trial on psilocybin for generalized anxiety disorder.
- **Duke University**, in Durham, NC, which will quantify cortisol, estradiol, interleukin 6 (IL 6), and interleukin 1β (IL 1β) from saliva samples to capture stress physiology, endocrine modulation, and inflammatory signaling.
- **Holobiome,** in Boston, which will contribute data through a large-scale clinical trial to identify microbiome-modulating interventions that target the gut-brain axis to decrease stress and anxiety.
- **The John Hopkins University School of Medicine**, in Baltimore, which will contribute data from 8 approved clinical trials on psilocybin use across a range of conditions.
- **Ksana Health**, in Eugene, OR, which will integrate continuous wearable device data with electronic health records at unprecedented scale to predict and prevent behavioral health disorders and promote healthy behaviors.
- **The University of Southern California**, in Los Angeles, which will contribute data from a trial on the feasibility and efficacy in healthy adults of psilocybin alone versus with eight weeks of mindfulness training.
- **The University of Wisconsin**, in Madison, which will contribute data from 3 approved psilocybin trials, seeking to dissociate the contributions of conscious psychedelic experience and non-conscious neurobiological mechanisms, as well as examining whether transcutaneous auricular vague nerve stimulation (taVNS) can augment durable outcomes following a single psilocybin session.
- **The Yale Stress Center**, in New Haven, CT, which will contribute data from an interventional clinical trial testing the effects of pregnenolone in individuals with alcohol use disorder.

Through EVIDENT, HHS and ARPA-H are building the science that will let promising rapid treatments to finally cross the finish line and become affordable options for Veterans and all Americans who need them.